tardive dyskinesia

Teva gains FDA approval for once-daily formulation of flagship drug Austedo
Fierce Pharma
Wed, 02/22/23 - 10:09 am
Teva Pharmaceutical
FDA
Austedo
tardive dyskinesia
Huntington's disease
Teva, after Lupin deal, holds another Austedo generic challenger to a 2033 launch
Fierce Pharma
Sun, 06/12/22 - 08:19 pm
Teva Pharmaceutical
Austedo
generics
patents
tardive dyskinesia
Aurobindo
Teva settlement prevents Lupin from launching its Austedo generic until 2033
Fierce Pharma
Mon, 05/2/22 - 06:34 pm
Teva Pharmaceutical
tardive dyskinesia
Austedo
Lupin
generics
Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market
Fierce Pharma
Fri, 05/28/21 - 11:14 am
Teva Pharmaceutical
tardive dyskinesia
DTC ads
Austedo
Lagging rival Neurocrine, Teva preps ad campaign in tardive dyskinesia
Fierce Pharma
Thu, 04/29/21 - 10:27 am
Teva Pharmaceutical
tardive dyskinesia
Austedo
DTC ads
Teva forecasts 'tenfold' growth for new launch Austedo. Why don't analysts agree?
Fierce Pharma
Wed, 11/20/19 - 10:26 pm
Teva Pharmaceutical
Austedo
Huntington's disease
tardive dyskinesia
Ingrezza-maker Neurocrine brings tardive dyskinesia awareness to the tube
Fierce Pharma
Fri, 01/25/19 - 11:06 pm
Neurocrine
tardive dyskinesia
television ads
New Neurocrine, Teva meds win doctors' praise, fueling bigger sales expectations
Fierce Pharma
Wed, 10/11/17 - 11:02 am
Neurocrine
Teva Pharmaceutical
physicians
Ingrezza
Austedo
tardive dyskinesia
Teva takes on Neurocrine with TD nod for Austedo
Fierce Pharma
Thu, 08/31/17 - 09:26 am
Teva Pharmaceutical
Neurocrine
Austedo
tardive dyskinesia
FDA
Neurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza
Seeking Alpha
Tue, 07/11/17 - 09:36 am
Neurocrine Biosciences
Ingrezza
tardive dyskinesia
Elagolix
uterine fibroids
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Marketwatch
Thu, 04/27/17 - 09:14 am
Neurocrine
drug pricing
Ingrezza
tardive dyskinesia
Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug
TheStreet.com
Wed, 04/12/17 - 11:48 am
Neurocrine
tardive dyskinesia
Ingrezza
Why Valbenazine Studies Seem Promising
Market Realist
Fri, 12/2/16 - 10:49 am
valbenazine
tardive dyskinesia
Neurocrine Biosciences
Positive PhIII leaves Neurocrine lining up for an FDA filing for tardive dyskinesia
Fierce Biotech
Thu, 10/8/15 - 09:32 am
Neurocrine
FDA
NBI-98854
tardive dyskinesia
Neurocrine To Move Tardive Dyskinesia Drug Into Phase 3
Yahoo/Zacks.com
Fri, 08/8/14 - 05:55 pm
tardive dyskinesia
Neurocrine Biosciences
NBI-98854
earnings
2 Biotechs Race To Treat Movement Disorders
Seeking Alpha
Fri, 06/27/14 - 09:23 am
movement disorders
tetrabenazine
Auspex Pharmaceuticals
Neurocrine Biosciences
tardive dyskinesia
chorea
Neurocrine Biosciences shares surge on study
Marketwatch
Mon, 01/6/14 - 04:58 pm
tardive dyskinesia
Neurocrine Biosciences
NBI-98854
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Wed, 09/11/13 - 11:25 am
Neurocrine
ChemoCentryx
CCX140
NBI-98854
tardive dyskinesia
diabetic nephropathy
Neurocrine Biosciences shares down on study
Yahoo/AP
Tue, 09/10/13 - 10:22 am
Neurocrine Biosciences
tardive dyskinesia
Why We Think Neurocrine's Phase IIb Trial Of NBI-98854 Will Be A Success
Seeking Alpha
Sat, 07/27/13 - 11:19 am
Neurocrine Biosciences
NBI-98854
tardive dyskinesia

Pages